Navigation Links
SomaLogic Inc. receives Grand Challenges tuberculosis biomarkers grant
Date:2/9/2012

Boulder CO SomaLogic, Inc., announced today that it will receive a tuberculosis (TB) biomarkers grant through the Bill & Melinda Gates Foundation's Grand Challenges in Global Health program, an initiative that seeks to overcome persistent bottlenecks in creating new tools that can radically improve health in the developing world. Urs Ochsner, head of the Infectious Diseases Research Group at SomaLogic, will pursue an innovative research project to identify and validate TB biomarkers, titled "SOMAmer-based detection of tuberculosis biomarkers."

The Grand Challenges TB Biomarkers program provides funding for groundbreaking research into TB biomarkers for the development of a low-cost, simple to use tool that can quickly and accurately diagnose TB in developing countries.

"There is an urgent need to break through barriers in biomarker research in order to develop a highly-sensitive point-of-care diagnostic to improve identification of active TB cases," said Chris Wilson, Director of Global Health Discovery at the Bill & Melinda Gates Foundation. "We hope these innovative ideas lead to effective and affordable TB diagnostics that can make an impact on one of the world's deadliest infectious diseases."

Dr. Ochsner's project is one of ten Grand Challenges TB biomarkers grants announced today. "The initial applications of our SOMAscan proteomic technology to detect certain protein biomarkers of the tuberculosis bacteria have been highly promising and exciting," said Dr. Ochsner. "We are both delighted and grateful to the Gates Foundation for their recognition of the potential of this work, and for their support in helping us bring it to the point where it can make a difference in literally millions of lives."

The most beneficial diagnostic TB test would need to measure both multiple TB bacterial proteins as well as the host proteins involved in the onset and progression of the disease. In addition, it must perform effectively in the conditions in the parts of the world where TB is most often rampant. SomaLogic's breakthrough proteomic technology, based on protein-detecting reagents called "SOMAmers," provides clear advantages over current reagents and methods used in TB tests in terms of accuracy, sensitivity, stability (e.g., no need for refrigeration), ease of production and cost: In short, all of the attributes necessary to develop a POC diagnostic device for remote and resource-poor areas of the world.

In line with the Gates Foundation's Global Access policy, SomaLogic is committed to ensuring that the knowledge gained during this project is promptly and broadly disseminated, and that diagnostic tests that come from this work will be made available and accessible at a reasonable cost to the developing world.


'/>"/>

Contact: Fintan Steele, Ph.D.
fsteele@somalogic.com
720‑214‑3080
SomaLogic, Inc.
Source:Eurekalert

Related biology news :

1. SomaLogic and Ambergen announce agreement for commercial applications of photocleavable biotin
2. SomaLogic announces agreement with leading global pharma company to accelerate R&D
3. SomaLogic and New England Biolabs announce agreement to use SOMAmers for multiple PCR products
4. SomaLogic researchers describe revolutionary new approach to protein analysis and application to early diagnosis of lung cancer
5. St. Josephs receives Canadas first whole-body PET/MRI scanner
6. Rensselaer Professor Ryan Gilbert receives NSF CAREER award
7. WHOIs John Waterbury receives NAS Gilbert Morgan Smith Medal
8. SUNY Downstate receives grant from research to prevent blindness
9. Startup receives $4 million to develop drug delivery targeted to the back of the eye
10. University of Texas chemist receives major grant to improve detection of drug-resistant tuberculosis
11. Kessler Foundation neuroscientist Jordan Grafman receives Humboldt Research Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/20/2016)... Dec. 20, 2016 The rising popularity ... and leasing is stoking significant interest in keyless ... technology, Bluetooth low energy (BLE), biometrics and near-field ... next wave of wireless technologies in the automotive ... to advanced access systems opens the market to ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
(Date:12/16/2016)... Research and Markets has announced the addition ... to 2021" report to their offering. ... The biometric vehicle access system market, ... of 14.06% from 2016 to 2021. The market is estimated to ... 854.8 Million by 2021. The growth of the biometric vehicle access ...
Breaking Biology News(10 mins):
(Date:1/23/2017)... 23, 2017 Atlas Genetics Ltd., the ... its Series D financing, raising $35 million from a syndicate ... Biotech. ... Development of the Atlas Genetics io® system has been completed ... test announced in February 2016.  This new Series D equity ...
(Date:1/21/2017)... ... January 20, 2017 , ... G&L Scientific Inc, ... industry ( http://www.gandlscientific.com ), has announced the opening of new offices in Cambridge, ... consultants and contractors. This is the latest step in G&L’s expansion of its ...
(Date:1/21/2017)... Aratana Therapeutics, Inc. (NASDAQ: PETX ... development and commercialization of innovative biopharmaceutical products for companion ... North America 2016. ... on the FDA approval of three innovative therapeutics in ... (capromorelin oral solution) and NOCITA ® (bupivacaine liposome ...
(Date:1/20/2017)... -- http://www.Financialbuzz.com - According to ... of death worldwide. There were 8.2 million cancer related ... deaths increased gradually over time, the death rates have ... cancers continues to drive demand of biological therapies for ... Insights, Inc. cancer biological therapy market size was USD 61.3 ...
Breaking Biology Technology: